Investing.com - Tcr2 Therapeutics (NASDAQ: TCRR) reported first quarter EPS of $-1.56, $0.76 worse than the analyst estimate of $-0.81. Revenue for the quarter came in at $0.00 versus the consensus estimate of $0.00.
Tcr2 Therapeutics's stock price closed at $1.47. It is up 73.21% in the last 3 months and down -50.00% in the last 12 months.
Tcr2 Therapeutics saw 1 positive EPS revisions and 1 negative EPS revisions in the last 90 days. See Tcr2 Therapeutics's stock price’s past reactions to earnings here.
According to InvestingPro, Tcr2 Therapeutics's Financial Health score is "weak performance".
Check out Tcr2 Therapeutics's recent earnings performance, and Tcr2 Therapeutics's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar